Organogenesis Holdings Inc (ORGO) Q2 2020 Earnings Call Transcript

Organogenesis Holdings Inc (ORGO 1.40%)
Q2 2020 Earnings Call
Aug 10, 2020, 5:00 p.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good afternoon, ladies and gentlemen, and welcome to the second-quarter 2020 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission including Item 1A, Risk Factors, of the company's most recent annual and quarterly report. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to this as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.

I would now like to turn the call over to Mr. Gary S. Gillheeney, Sr., Organogenesis Holdings' president and chief executive officer. Please go ahead, sir.

Gary Gillheeney -- President and Chief Executive Officer

Thank you, and welcome, everyone, to Organogenesis Holdings second-quarter 2020 earnings conference call. I'm joined on the call today by Tim Cunningham, our chief financial officer. Now let me start with a brief agenda of what we will cover during our prepared remarks. I'll start with an overview of our revenue performance in the second quarter, including the improving business trends we experienced during the quarter and the areas of our business that have performed extremely well despite the challenging operating environment.

After my opening remarks, Tim will provide you with a more in-depth review of our quarterly financial results and the formal financial guidance we reinstituted in this afternoon's press release, as well as a summary of our balance sheet and financial condition. And then we will open up the call for questions. I'll begin with the review of our second-quarter revenue performance. We reported total revenue growth of 6% year over year in the second quarter driven by 8% growth in sales in our Advanced Wound Care products, which offset a 5% decrease in sales of our Surgical & Sports Medicine products compared to the prior year.

Our revenue results were well above expectations and exceeded the high end of our preliminary revenue range that we announced on July 15. We believe our second-quarter results were particularly impressive given the unprecedented level of uncertainty and business disruption caused by the global pandemic beginning in mid-March. Simply stated, we believe our second-quarter revenue performance is a direct result of the organization's resilience in the face of these unprecedented challenges and the dedication of our employees to our customers and patients. Our growth in Q2 reflects a continuation of the key drivers of our growth, which we've talked about in each of our earnings call.

One, the investment that we've made to expand our sales force over the recent years, strong execution of our commercial strategy and the benefits of our comprehensive portfolio and solutions we offer in the Advanced Wound Care and Surgical & Sports Medicine markets. After a difficult start to the second quarter in which year-over-year sales declined 29% for the month of April, we saw business trends begin to improve in May as many healthcare facilities began to reopen, reduced restrictions on access to their facilities and resumed patient consultations and treatments. By the end of May, more than 80% of accounts that we service were open, compared to 70% at the end of April. We also saw early signs of improving activity at these accounts with roughly 50% accepting new patients at the end of May, compared to less than 10% in April.

Business trends improved significantly during the month of June, as well as we ended the month with more than 90% of accounts open and all of them accepting new patients. We also saw improving trends related to the percentage of accounts allowing access to sales reps, which improved to 65% in June, compared to less than 10% access at the end of April. We were pleased to see the improving business trends in May and June. And importantly, we were well-positioned to drive strong growth as the environment improved given our competitive advantages in three areas: one is our broad portfolio of products with strong brand recognition that allows us to treat patients' needs throughout the wound healing process; second, our business mix, both in terms of site of care and geographic regions favorite areas that were less impacted by the disruptions caused by COVID-19; and third, our commercial strategy focused on leveraging multiple channels, new product introductions and brand loyalty for our products.

So in summary, after a difficult start to the quarter where we saw sales declined 29% year over year in April, our total sales for May and June together increased 24% year over year. And notably, the 24% increase in sales in May and June were driven by improving sales trends in both Advanced Wound Care and our Surgical & Sports Medicine product groupings, which increased 24% and 20% year over year, respectively. The growth trends in sales of Advanced Wound Care products improved in each month of the second quarter and posted year-over-year growth in both May and June. The growth trends in our Surgical & Sports Medicine business improved in May, but were still down in the high single digits year over year and posted very strong year-over-year growth in June.

We are pleased with our second-quarter performance. The fundamentals of our business and strategy remain strong, and we are well-positioned to deliver strong operating and financial performance over the balance of 2020. As such, we reinstated our formal financial guidance, reflecting our expectations for total revenue growth of 5% to 6% in 2020. We believe it's noteworthy that this growth range is the same as the one we introduced as part of our initial 2020 revenue outlook on our Q4 2019 call back in March before the global pandemic disrupted the U.S.

operating environment. So with that, let me turn it over to Tim for a review of our financial results for the second quarter and our balance sheet.

Timothy Cunningham -- Chief Financial Officer

Thank you, Gary. I will begin with a review of our second-quarter financial results. Unless otherwise specified, all growth rates referenced during my prepared remarks are on a year-over-year basis. Net revenue for the second quarter of 2020 was $69 million, compared to $64.9 million for the second quarter of 2019, an increase of $4 million or 6%.

Second-quarter revenue results came in above the high end of the preliminary revenue range provided on July 15. Revenue from Advanced Wound Care products for the second quarter of 2020 was $59.7 million, compared to revenue of $55.2 million for the second quarter of 2019, an increase of $4.5 million or 8%. Revenue from Advanced Wound Care products represented 87% of total revenue in the second quarter of 2020, compared to 85% of total revenue in the prior-year period. Revenue from Surgical & Sports Medicine products for the second quarter of 2020 was $9.2 million, compared to $9.7 million for the second quarter of 2019, a decrease of $0.5 million or 5%.

Revenue from Surgical & Sports Medicine products represented 13% of total revenue in the second quarter of 2020, compared to 15% of total revenue in the prior-year period. Revenue from PuraPly products for the second quarter of 2020 was $28.5 million, compared to $29.7 million in the second quarter of 2019, a decrease of $1.2 million or 4%. Revenue from PuraPly products represented approximately 41% of total revenue in the second quarter of 2020, compared to 46% of total revenue in the second quarter of 2019. As of June 30, 2020, we had approximately 285 direct sales representatives, compared to 265 at year-end 2019 and approximately 160 independent agencies, compared to 160 at year-end 2019.

Gross profit for the second quarter of 2020 was $48.9 million, compared to $45.5 million for the second quarter of 2019, an increase of $3.4 million or 8%. Gross profit margin for the second quarter of 2020 was 71% of revenue, compared to 70% of revenue for the second quarter of 2019. The increase in gross profit and gross profit margin resulted from increased sales volumes, primarily strength in our Advanced Wound Care products and changes in product mix. Operating expenses for the second quarter of 2020 were $51.2 million, compared to $52.8 million for the second quarter of 2019, a decrease of $1.7 million or 3%.

The decrease in operating expenses in the second quarter of 2020 as compared to the second quarter of 2019 was driven primarily by lower selling, general and administrative expenses, which decreased to $46.5 million, compared to $49 million in the second quarter of 2019, a decrease of $2.5 million or 5%. The decrease in selling, general and administrative expenses is primarily due to: reduced travel and marketing programs amid COVID-19-related travel restrictions; a decrease in amortization associated with intangible assets; and a decrease in legal, consulting fees and other costs associated with the ongoing operations of our business. These decreases in SG&A expenses were offset partially by an increase in expenses due to additional headcount, primarily in our direct sales force. R&D expense was $4.7 million for the second quarter of 2020, compared to $3.9 million in the second quarter of 2019, an increase of $0.8 million or 21%.

The increase in R&D was driven by additional headcount and continued investment in clinical programs and our product pipeline. Total operating expenses for the second quarter of 2020 were $51.2 million, a $6.9 million or 12% decrease from $58 million of operating expenses in the first quarter of 2020. The $6.9 million reduction in operating expenses this quarter represents better-than-expected performance against -- versus our stated goal to reduce expenses by $5 million to $6 million in the quarter and is a direct result of our proactive efforts to identify and implement cost savings measures as a result of the rapidly evolving environment and continued uncertainty resulting from the impact of COVID-19. These cost savings measures were primarily related to: discontinuing all nonessential services and programs; instituting controls on discretionary spending, including travel, events, marketing; and temporary delays in some clinical spending.

Operating loss for the second quarter of 2020 was $2.3 million, compared to an operating loss of $7.3 million for the second quarter of 2019, a decrease of $5.1 million or 69%. Total other expenses for the second quarter of 2020 was $2.9 million, compared to $2.3 million for the second quarter of 2019, an increase of $0.6 million or 25%. The increase was driven primarily by higher interest expense related to increased borrowings compared to the prior-year period. Net loss for the second quarter of 2020 was $5.2 million or 5% -- $0.05 per share, compared to a net loss of $9.6 million or $0.11 per share for the second quarter of 2019, a decrease of $4.5 million or 46%.

Adjusted EBITDA of $274,000 for the second quarter of 2020, compared to an adjusted EBITDA loss of $4.8 million for the second quarter of 2019, an increase of $5.1 million or 106%. We have provided a full reconciliation of our adjusted EBITDA results in our earnings release, Form 8-K and Form 10-Q, all of which were filed with the SEC this afternoon. Turning to a brief review of our financial results for the six months ended June 30, 2020. Net revenue for the six months ended June 30, 2020, was $130.7 million, compared to $122.1 million for the first six months of 2019, an increase of $8.6 million or 7%.

The increase in net revenue was driven by an increase of $8 million or 8% in net revenue of Advanced Wound Care products and an increase of $0.7 million or 3% in net revenue of Surgical & Sports Medicine products compared to the prior year. Net revenue of PuraPly products for the six months ended June 30, 2020, was $61 million, compared to $55.1 million for the first six months of 2019, an increase of $5.9 million or 11%. Net revenue of PuraPly products represented approximately 47% of net revenue for the six months ended June 30, 2020, compared to 45% for the first six months of 2019. Gross profit for the first six months of June -- for the six months ended June 30, 2020, was $91.9 million or 70% of revenue, compared to $85.6 million or 70% of net revenue for the first six months of 2019, an increase of $6.2 million or 7%.

Operating loss for the six months ended June 30, 2020, was $17.3 million, compared to an operating loss of $19.4 million for the first six months of 2019, a decrease of $2.1 million or 11%. Net loss for the first six months -- for the six months ended June 30, 2020, was $21.5 million or $0.21 per share, compared to a net loss of $25.3 million or $0.28 per share for the first six months of 2019. Turning to the balance sheet. As of June 30, 2020, the company had $40.5 million in cash and $115.3 million in debt obligations, of which $16.3 million were capital lease obligations, compared to $60.2 million in cash and $100.6 million in debt obligations, of which $17.5 million were capital lease obligations as of December 31, 2019.

The net change in cash of approximately $19.6 million for the six months ended June 30, 2020, is driven by $13.1 million of cash provided by financing activities offset by $26.6 million of cash used in operating activities and $6.1 million of cash used in investing activities during period. As of June 30, 2020, we were in compliance with the financial covenants under the credit agreement with Silicon Valley Bank. At quarter end, we had $60 million of outstanding borrowings under the term loan facility and $39.4 million of borrowings on the revolving facility. We expect that our cash on hand as of June 30, 2020, cash flows from product sales, will be sufficient to fund our operating expenses, capital expenditure requirements and debt service payments for at least the 12 months following the filing of our 10-Q.

Turning to a review of our 2020 revenue guidance. As detailed in our press release this afternoon, we are reinstituting fiscal-year 2020 revenue guidance originally issued on March 9, 2020. For the 12 months ended December 31, 2020, the company now expects net revenue of between $273 million and $277 million, representing growth of approximately 5% to 6% year over year, as compared to net revenue of $261 million for the 12 months ended December 31, 2019. The 2020 net revenue guidance range assumes: net revenue from Advanced Wound Care products of between $236 million and $238 million, representing growth of approximately 7% to 8% year over year, as compared to net revenue of $221 million for the 12 months ended December 31, 2019; net revenue from Surgical & Sports Medicine products of between $37 million and $39 million, representing a decrease of approximately 3% to 8% year over year, as compared to net revenue of $40 million for the 12 months ended December 31, 2019; net revenue from the sale of PuraPly products of between $108 million and $110 million, representing a decrease of approximately 13% to 15% year over year, compared to net revenue of $127 million for the 12 months ended December 31, 2019.

In addition to the formal revenue guidance, we would also like to provide a few additional considerations when evaluating our growth expectations for fiscal-year 2020. You may recall that we introduced additional assumptions supporting our fiscal-year 2020 revenue guidance during our Q4 2019 call in March. This additional color is intended to help the investment community better understand the assumptions supporting our revenue expectations for 2020. First, the largest contributor to our total company net revenue growth in fiscal-year 2020 will be sales of our amnion products which, at the midpoint of our full-year range, assumes amnion growth of approximately 60% year over year in 2020.

Second, we expect sales of our remaining non-PuraPly, non-amnion products, which collectively form the group we call PMA and Other, to decrease at the midpoint of the range, approximately 8% year over year in 2020. The expected year-over-year decline in non-PuraPly, non-amnion products is largely a result of the softer sales performance in Q2 due to the COVID-19-related business disruptions. Third, the midpoint of our fiscal-year 2020 net revenue guidance assumes PuraPly sales decline approximately 14% this year, which reflects our expectation that PuraPly sales would decrease by approximately 45% to 50% year over year in the fourth quarter of 2020 following the transition to the high-cost bundle beginning on October 1, 2020. With that, operator, I'll turn the call back over to you.

Questions & Answers:

Operator

Thank you. [Operator instructions] And our first question will come from Matt Miksic. Sir, your line is now open.

Matt Miksic -- Credit Suisse -- Analyst

Great. Thanks so much for taking our questions, and congrats on what was a pretty strong quarter in a pretty tough environment. In fact, I'm looking at the growth rate, and if I'm not mistaken, it might be the best top-line growth rate in our universe this quarter. So I know 6% wasn't where you started out aiming at for the year, but congrats on a pretty -- for handling Q2 pretty well.

Gary Gillheeney -- President and Chief Executive Officer

Thank you, Matt.

Matt Miksic -- Credit Suisse -- Analyst

You bet. So a lot to follow up on, but I wanted to focus on a couple things. One was the sort of the strength in amnion and what you can say maybe about your supply levels, the trajectory of that growth in the quarter and maybe how it differed across sites of care. And I don't want to stress this too much, but there's competitive landscape, if it's changing, if you anticipate it changing.

One of your old friends is getting refunded and recapitalized and expect, I guess, to be back out in the market and how we should think about that. And then I have one follow-up.

Gary Gillheeney -- President and Chief Executive Officer

Sure. Regarding our amnions, I think what's important is we relaunched Affinity, which certainly had a significant impact on the quarter, the product selling extremely well, and also our strategy of diversifying our sites of care and our offerings in those sites of care. So as we focused on the office, that allowed us to continue to sell not only just our amnions, but also our other products that are designed for that site of care. So we're pretty excited about how our amnions are performing, excited about the relaunch of Affinity.

And yes, we have a new manufacturer. So our supply of Affinity is much stronger than it ever was, and we're continuing to build that capacity as we go forward as the demand continues to increase. So sites of care were important for Affinity, as well as, obviously, the other products that we have and the supply that we have. On the competitive landscape, we really haven't seen much of a change yet, though other competitors are certainly stepping back in.

Affinity is the only fresh amniotic product in the space. We're pretty excited about that. PuraPly is still a very strong product, particularly in the office, in outpatient setting. So we're pretty excited and pretty confident that our portfolio will withstand anything that we see in the competitive environment today.

The other thing that's interesting is we still have access -- we only have access to 65% of the wound care centers, but we virtually have been connected to about 100% of our customers. So we've continued to build our brand and our relationships during this difficult time, and we think that will pay dividends for us down the road as well.

Matt Miksic -- Credit Suisse -- Analyst

Great. That's helpful color. And then just on PuraPly, I'm sure you'll get some other questions on this. But given that you're looking at the down 45% to 50% in Q4 and down 14% for the year, how -- I know you started the year with a strategy in mind to expand the number of SKUs under that brand and sort of buffer that business a little bit from the kinds of sharp declines that might be implied by the expiration of the pass-through reimbursement.

I guess what have you learned so far? Maybe how has your thinking changed, if at all? And maybe what kind of assumptions are baked into that down 14% at this point?

Gary Gillheeney -- President and Chief Executive Officer

Sure. I'll start. And Tim, if you want to jump in, that's fine. So we have launched additional SKUs.

We have expanded the PuraPly offering and the number of accounts in the office that are utilizing PuraPly. So that will have a significant impact in holding the brand and holding the product. We've also launched our XT line extension of PuraPly, which is selling very well. We just recently launched that and expect that product to continue to grow to help offset any decline in PuraPly sales.

Tim, I don't know if you have anything to add?

Timothy Cunningham -- Chief Financial Officer

No. I think the only thing I would add to that, Matt, is that we started the year with PuraPly being down 40% to 45%. So I think it really hasn't evolved or changed. We're pleased with the line extensions and XT, as Gary mentioned.

But the majority of the decline is really just due to the effect of COVID.

Matt Miksic -- Credit Suisse -- Analyst

OK. All right. That's helpful. And I guess just to clarify, Gary, your comment on XT, recently launched.

Is that effect, I guess, on the potential growth or decline in PuraPly still sort of uncertain? Or what are your assumptions in terms of the success of that product?

Gary Gillheeney -- President and Chief Executive Officer

Right now, we're very confident in the product. It's selling extremely well. We thoughtfully launched it in only certain regions of the country, and it's performing above our expectations at this point. So we think it will be a strong contributor to help offset any ASP impact on the larger sizes that we have that are impacted by pass-through.

So we're very confident. As Tim mentioned, Q4 is impacted not just by the ASP, but the impact of COVID and rebounding from that. But we think XT will be a strong contributor to the growth of PuraPly post pass-through.

Matt Miksic -- Credit Suisse -- Analyst

Excellent. Very helpful. I'll hop back in queue. Thanks so much.

Gary Gillheeney -- President and Chief Executive Officer

Thank you.

Operator

Thank you. Now our next question is from the line of Ryan Zimmerman. Sir, your line is now open.

Ryan Zimmerman -- BTIG Research -- Analyst

Hey. Thank you. And let me echo Matt's sentiments, really a strong performance in light of everything. So maybe just to begin, Gary and Tim.

I was just curious. With everything that happened in the second quarter and how clinics reopened, I was just wondering how much impact, maybe either backlog or a surge, occurred in June and kind of how you're thinking about that, if at all, into the third quarter? And then I have a follow-up.

Gary Gillheeney -- President and Chief Executive Officer

We really didn't see a big impact of backlog in June at all, certainly not in Advanced Wound Care and not as -- a little bit more maybe in the Surgical & Sports Medicine area. But on the Surgical & Sports Medicine side, 75% of our business is in sort of the nonmetropolitan area. So they did fairly well once we got through May. They rebounded extremely well in June.

So there was some backlog there, but we don't have a lot of backlog built into our Q3 or Q4.

Ryan Zimmerman -- BTIG Research -- Analyst

Got it. That's helpful, Gary. And then the rep hiring did continue to increase, but at the same time, productivity levels improved sequentially, which is quite impressive given what other peers have seen in this quarter. So can you just talk to us about your longer-term views on what the appropriate rep levels are, maybe some thoughts around productivity and kind of where you think you can take that just to kind of help us frame out continued expansion of your sales force?

Gary Gillheeney -- President and Chief Executive Officer

Well, certainly an area -- it's an area we focus a lot of attention on, and it speaks to our portfolio as we get deeper, and you've heard me say this on other calls, we continue to get deeper and deeper into our accounts as we utilize our portfolio with new additions, such as Affinity, which is a readdition, and PuraPly XT, which is a new addition. We expect that to continue to grow. And our expectations for reps, we'd like to get to 300 to 315 or 310 probably at the end of the year. We'd like to see our agencies go up to around 170 to 180.

And we expect productivity improvements in each of those areas, both the agencies and our direct reps, each year as we launch new products. So it's important when you -- for us that we strategically put product offerings in different sites of care, one, to maximize the potential of the product, but also not to cannibalize other products. So we're continuing to improve the productivity of our sales reps. So we -- our guide has always been $1 million per rep.

We exceed that, and we will continue to exceed that, but our goal is to improve that every year.

Ryan Zimmerman -- BTIG Research -- Analyst

That's very helpful. And then just the last one for me and I'll hop back in queue. With the dynamic that's occurring in the fourth quarter with PuraPly, I wonder if you could maybe talk to us about your underlying assumptions for unit growth in spite of the changes to reimbursement for PuraPly and how that may play out or kind of what you're hoping for into next year from an underlying basis. Thanks for taking my question, and again, very strong performance.

Gary Gillheeney -- President and Chief Executive Officer

Great. Sure. Thank you. We certainly expect units to grow next year for PuraPly in Q4, and I'll defer to Tim.

We expect there to be a slight decline. That's typically what we experience. So pass-through only affects our larger-sized products, which for us is two. So those sales will decline, and we will eventually see the units increase as those larger wounds revert to some of the product offerings that we'll add to the bundle that can handle those wounds.

And because of our office strategy, there are solutions in the office for those larger wounds, but it will take a little time. It's usually a quarter and a half where we start to see the units to grow beyond the previous year. So there'll be a quarter, quarter and a half decline in units, but then you'll see growth in the office and you'll see more in the HOPD, which is the outpatient setting, as those larger wounds utilize some of our new offerings that we'll be putting out in October.

Ryan Zimmerman -- BTIG Research -- Analyst

Thank you.

Operator

Thank you. Our next question is coming from the line of Richard Newitter. Sir, your line is now open.

Richard Newitter -- SVB Leerink -- Analyst

Hi. Thanks, guys, and congrats on delivering growth and expecting growth and actually providing an outlook. You certainly will stand out this quarter. A couple questions here just on Affinity and the amnion portfolio broadly, too, if you can comment on that.

What surprised you most, I would say, in the quarter, if anything? And with respect to Affinity accounts and utilization relative to maybe what your expectations would have been for the relaunch of this, who's using it and where and is this existing customers? Or what's the mix of the customer base for that product in particular?

Gary Gillheeney -- President and Chief Executive Officer

Sure. It's primarily in the office right now. So we've strategically launched it in certain areas of the country in the office only, and we have historical users of the product. As you know, the product was sold in 2018, but we've been able to add additional customers at a very rapid rate.

So the product is selling extremely well. It's exceeded our expectations at this point in time, and we'll continue to expand the office offering as capacity expands.

Richard Newitter -- SVB Leerink -- Analyst

Great. And I'm just curious, beyond Affinity, anything else in the portfolio that surprised you positively or negatively, in particular, during the quarter? And then I have one follow-up.

Gary Gillheeney -- President and Chief Executive Officer

Well, what was interesting is what we call our PMA and other products like Apligraf and Dermagraft, which are the gold standard in wound care in our opinion. And certainly, the anchors of our wound care -- Advanced Wound Care market grew extremely well. In fact, was some of our higher growers. And what we learned is what we believe is the brand equity of those products, and particularly in a time of crisis, going back to something that you know it works, you know it's going to be reimbursed, it's covered by 1,500 private payers, it just was a migration back to those products immediately, that was a bit of a surprise.

Our strategy of moving more into the office, we weren't surprised that wounds and other procedures moved to the office when hospitals and outpatient centers were closed, but the pace in which they moved was a bit surprising to our advantage. So fortunately, our strategy paid dividends for us, and COVID actually helped drive that strategy. So I think those are the two surprising things. The launching of two products, we launched PuraPly XT and Affinity in the midst of a crisis and both have exceeded our expectations.

Affinity is already beyond the run rate that we exited in 2018 in a very short period of time. So I think those things, the brands -- the strong brands, our PMA products did extremely well, the office space business grew even faster than we thought and launching two new products in the middle of all of this went very well.

Richard Newitter -- SVB Leerink -- Analyst

Great. And if you would, I appreciate that you have different mix between metropolis-based accounts and maybe kind of more rural accounts. But in areas that are seeing surges or resurgences of the virus, I'm just curious if you can comment on any trends or potentially signs of retreat or if not, that would be helpful just given that there's different trends that are starting to emerge across the country. Thanks.

Gary Gillheeney -- President and Chief Executive Officer

Sure. Well, we're definitely seeing trends -- negative trends in the Texas area, Arizona, as well as in the Miami area. So we're seeing some of those trends. Fortunately, again, we're not in the metropolitan areas like Miami or some Houston, Dallas areas.

But we are starting to feel a little bit of it in those markets. We're seeing a little bit of a slowdown. So we've been -- it's one of the reasons we're a little cautious in our guidance in the Surgical & Sports Medicine business for the second half of the year. But most of the business that we have, as I said, is in the nonmetropolitan area.

So we don't expect to see a significant decline if there is a large rebound.

Richard Newitter -- SVB Leerink -- Analyst

Thank you.

Operator

Thank you. [Operator instructions] And our next question is from the line of Steven Lichtman. Your line is now open.

Steven Lichtman -- Oppenheimer -- Analyst

Thank you. Hi, guys, and congratulations on the quarter. Just wanted to follow up on the last -- prior question around backlog. The May, June growth was very impressive.

You mentioned, Gary, that you didn't see the growth being driven by backlog. Looking forward, do you see deferred procedures, say, from that late March and April time frame, therefore being an incremental tailwind still to come and potential upside driver?

Gary Gillheeney -- President and Chief Executive Officer

We do more on the Surgical & Sports Medicine side, but we do see that as a potential tailwind for us in the end of Q3 and more so in Q4. We don't see a lot of backlog in the Advanced Wound Care side because many of those wounds, I think, moved to the office because we're seeing a significant growth in the office. We are clearly taking share in the office, but I believe a lot of those wounds are wounds that would have been treated in an Advanced Wound Care outpatient center are being treated in the office. So I think we've absorbed some of that.

There should be some, but not significant on the Advanced Wound Care side, in my opinion.

Steven Lichtman -- Oppenheimer -- Analyst

Great. Thanks, Gary. And then just secondly, on the pipeline. We're getting a little closer, I think, to the TransCyte launch.

I think you talked in the medium term here. How should we be thinking about your preparations for launch there? And what kind of work needs to get done? And then also just wanted to ask you with respect to ReNu, whether that trial has restarted as well.

Gary Gillheeney -- President and Chief Executive Officer

Yeah. So regarding TransCyte, which we're looking to launch at the end of 2021 at this point, so our preparation is we need to build a direct sales force. That will be in the process of starting. We think it's a very concentrated market, one that we think we can serve with a small group of sales folks, 28 -- I think 128 centers that we'd be calling on, control about 40% of the market.

So that's important. So that's part of the strategy. We're also still working on TransCyte to get the manufacturing process, which as you know, we were reengineering that process to keep the capacity where it needs to be to meet demand, but also to keep the margins where they need to be. So that work is still going on.

So building the sales force and continuing to make sure the manufacturing process is robust is what our focus is. Regarding ReNu, ReNu-- most of the clinical work for ReNu is on hold right now partly because of spending holds that we put on the product -- on the project because of COVID. We now expect to ramp that back up at the end -- during Q3 and expect to start that trial in Q4 of this year, Q1 of next year. COVID has had an impact generally on all of our clinical work in some way, shape or form, but we expect Q4 or Q1 that the ReNu trial will begin.

Steven Lichtman -- Oppenheimer -- Analyst

Understood. Thanks, Gary. Appreciate it.

Gary Gillheeney -- President and Chief Executive Officer

Sure.

Operator

Thank you. We are currently showing no remaining questions in the queue at this time. That does conclude our conference for today. Thank you for your participation.

Gary Gillheeney -- President and Chief Executive Officer

Thank you.

Timothy Cunningham -- Chief Financial Officer

Thank you.

Duration: 46 minutes

Call participants:

Gary Gillheeney -- President and Chief Executive Officer

Timothy Cunningham -- Chief Financial Officer

Matt Miksic -- Credit Suisse -- Analyst

Ryan Zimmerman -- BTIG Research -- Analyst

Richard Newitter -- SVB Leerink -- Analyst

Steven Lichtman -- Oppenheimer -- Analyst

More ORGO analysis

All earnings call transcripts